APC and colorectal cancer: Inhibition of the aberrantly activated WNT/β-catenin/APC pathway could be the most attractive therapeutic target, as mutations of APC are present in up to three-fourths of colorectal cancers and remaining cases have common mutations in other components of the pathway [12, 13].